MAINTENANCE TREATMENT WITH ALEMTUZUMAB Campath AS AN ALTERNATIVE TO ALLOGENIC TRANSPLANTATION IN PATIENTS WITHOUT COMPATIBLE DONOR IN PATIENTS WITH PERIPHERAL T CELL LYMPHOMA - ND

G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI0 个研究点目标入组 25 人开始时间: 2006年8月3日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•- Histologically confirmed diagnosis of Peripheral T cell Lymphoma Entheropathy-type T-cell Lymphoma; Hepatosplenic T-cell Lymphoma; Subcutaneous Panniculitis-like T-cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Peripheral T-cell Lymphoma, unspecified - Stage I IV - Performance Status ECOG 0 3 - Age 18 65 years - CD52 positivity - Previous induction therapy with CHOP or DHAP, followed by autologous bone marrow transplantion - Complete or partial 75 response at the time of inclusion into the study - HIV, HbsAg, HCV negativity - CMV Ag and/or Ab anti CMV IgM negativity - ANC 1.500 x 109/L and PLT 75 x 109/L - Normal renal and hepatic functions - LVEF 50 - Documented absence of infections - No previous or concomitant neoplasms - No CNS involvement - Use of effective contraception - Negative pregnancy test - Written Informed Consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- Cardiopathy- LVEF 40 - No previous treatment - Myelodysplasic syndromes - HbsAg, HIV and HCV-RNA positivity

发起方

G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI